Hormore replacement therapy and the prevention of cardiovascular disease

Human Reproduction Update

Volumn 8, Issue 3, 2002, Pages 201-215

  Teede, Helena J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Health management; Hormone replacement therapy; Lifestyle modification; Preventative therapy

Indexed keywords

CONJUGATED ESTROGEN; DAIDZEIN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTRONE SULFATE; ETHINYLESTRADIOL; GENISTEIN; GESTAGEN; GESTODENE; LIGAND; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; PHYTOESTROGEN; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; RALOXIFENE; RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; STEROID HORMONE; TESTOSTERONE; TIBOLONE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNINDEXED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; FEMALE; HORMONE ACTION; HORMONE STRUCTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; LIPID METABOLISM; MALE; NONHUMAN; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THROMBOSIS; ANIMAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; MORTALITY;

ANIMALS; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; POSTMENOPAUSE;

EID: 0035985967     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/8.3.201     Document Type: Review

References (173)

1. Medroxyprogesterone acetate antagonises inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
2. Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone
3. Cardiac rehabilitation and secondary prevention of coronary heart disease
4. Epidemiology of phytoestrogens
5. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
6. Kinetics and pharmacology of estrogens in pre- and postmenopausal women
7. Meta-analysis of the effects of soy protein intake on serum lipids
8. Effects of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomised controlled trial
9. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework
10. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial
11. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
12. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women
13. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women
14. Postmenopausal estrogen and prevention bias
15. Hormone replacement therapy, heart disease and other considerations
16. Postmenopausal estrogen use and heart disease risk factors in the 1980s
17. Estrogen receptors and cardiovascular disease
18. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
19. Estrogen-like substances in plants
20. 17Beta-oestradiol enhances nitric oxide synthase activity in endothelium-denuded rat aorta
21. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits
22. Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous sequential progestin
23. Guest editorial: The AHA guidelines on hormone replacement therapy and cardiovascular disease
24. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the lipid research clinics program follow-up study
25. SERMs and cardiovascular disease in women. How do these agents affect risk?
26. Estrogens, progestins, and coronary heart disease in cynomolgus monkeys Fertil
27. The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease
28. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
29. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys
30. The Coronary Drug Projects initial findings leading to modifications of the research protocol
31. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial)
32. Comparison of transdermal and oral oestrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins
33. Effects of dietary phytoestrogens in postmenopausal women
34. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP
35. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
36. Chemistry of antihormones
37. Thrombosis and acute coronary artery lesions in sudden cardiac ischaemic death
38. Phytoestrogens in health and disease
39. Personal perspective on low-dosage estrogen therapy for postmenopausal women
40. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
41. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement
42. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury
43. Diabetes, obesity and cardiovascular disease
44. Aspirin in the treatment and prevention of cardiovascular disease
45. Low-dose esterified estrogen therapy: Effect on bone, plasma estradiol concentrations, endometrium and lipid levels
46. Heart disease in women
47. Exercise and heart disease in women: Why, how and how much?
48. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000
49. Modulation of coronary vascular resistance in female rabbits by estrogen and progesterone
50. Hormone therapy to prevent disease and prolong life in postmenopausal women
51. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
52. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
53. Postmenopausal hormone therapy and mortality
54. A prospective, observational study of postmenopausal hormone replacement therapy and primary prevention of cardiovascular disease
55. The effects of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with angina pectoris
56. A double blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
57. Effect of 17β estradiol on pre-existing atherosclerotic lesions: Role of the endothelium
58. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
59. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women
60. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: Implications for atherosclerosis
61. MRC/BHF Heart Protection Study of cholesterol- lowering therapy and anti-oxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death
62. Value of drug-licensing documents in studying the effect of postmenopausal HRT on cardiovascular disease
63. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
64. Effects of estrogen replacement therapy on the progression of coronary artery atherosclerosis
65. Estrogen replacement and brachial artery flow mediated vasodilation in older women
66. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells
67. Effects on mortality of metoprolol in acute myocardial infarction: A double blind randomised trial
68. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: A randomised controlled trial in humans
69. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial
70. Increased risk of recurrent venous thromboembolism during hormone replacement therapy
71. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism. Results from a randomised, double-blind, clinical trial
72. The effects of disease severity and sex on coronary endothelium-dependent vasomotor function in an atherosclerotic primate model
73. Reduced or modified dietary fat for preventing cardiovascular disease
74. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women
75. Diet, lifestyle and the risk of type 2 diabetes mellitus in women
76. Acute and subacute effects of naturally occurring estrogens on luteinizing hormone secretion in the ovariectomized rat: Part 2
77. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
78. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein
79. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
80. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3
81. Estrogen receptors: Bioactivities and interactions with cell signaling pathways
82. C-reactive protein: Risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
83. The effects of phytoestrogens on menopausal symptoms in postmenopausal women
84. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
85. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta
86. Acute effects of hormone replacement therapy with tibolone on myocardial ischaemia in women with angina
87. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors and carbohydrate metabolism
88. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years
89. The impact of diabetes mellitus on survival after myocardial infarction: Can it be modified by drug treatment?
90. Treatment of postmenopausal osteoporosis with transdermal estrogen
91. Hormone replacement therapies in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997
92. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta
93. A prospective study of maturity onset diabetes and risk of coronary heart disease and stroke in women
94. Lipoprotein (a) concentration and apolipoprotein (a) size. A synergistic role in advanced atherosclerosis?
95. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
96. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women
97. Mechanisms of disease: The protective effects of estrogen on the cardiovascular system
98. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women
99. The role of hormone replacement therapy in the prevention of postmenopausal heart disease
100. Hormone replacement therapy and myocardial infarction
101. Guide to preventive cardiology for women
102. Awareness, perception and knowledge of heart disease risk and prevention among women in the United States
103. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association
104. Design and methods of the Raloxifene Use for the Heart (RUTH) study
105. Cardiovascular effects of raloxifene: Data from preclinical studies and clinical trials in postmenopausal women
106. What is the role of phytoestrogens in treating menopausal symptoms
107. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment
108. Effect of combined oral hormone replacement therapy on tissue factor pathway inhibitor and Factor VII
109. The acute effects of sublingual 17beta-estradiol on the cardiovascular system
110. Influence of sex hormones on plasma endothelin levels
111. Resistance exercise in individuals with and without cardiovascular disease: An advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology
112. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
113. Naturally occurring oestrogens in foods - A review
114. Hormone replacement therapy and serum angiotensin-converting enzyme activity in postmenopausal women
115. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
116. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women
117. Effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women
118. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys
119. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
120. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial
121. Follicular depletion during the menopausal transition: Evidence for accelerated loss and ultimate exhaustion
122. Hormone replacement therapy and increased plasma concentration of C-reactive protein
123. Treatment of myocardial infarction in the United States: Observations from the national Health Registry of myocardial infarction
124. Beneficial effects of estrogen on exercise-induced myocardial ischaemia in women with coronary artery disease
125. Acute anti-ischemic effect of estradiol in postmenopausal women with coronary artery disease
126. The pathogenesis of atherosclerosis: A perspective for the 1990s
127. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
128. Estrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women
129. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
130. Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: A randomized, placebo-controlled, double-blind, parallel group trial
131. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease
132. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
133. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells
134. Progestins and the cardiovascular system
135. Noninvasive assessment of endothelial vasomotor function
136. Primary prevention of coronary heart disease in women through diet and lifestyle
137. Structure-function relationships and estrogens and progestins
138. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia
139. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting
140. Postmenopausal estrogen use and coronary atherosclerosis
141. Estrogen inhibits the response-to-injury in a mouse carotid artery model
142. Effects of dietary soybean estrogens on the reproductive tract in female rats
143. Endocrine changes across the Perimenopause
144. Dietary prevention of cardiovascular disease
145. Cardiovascular effects of sex hormones
146. Postmenopausal hormone replacement therapy increases both coagulation activity and fibrinolysis
147. Platelet aggregation is not reduced in postmenopausal women on oral hormone replacement therapy
148. Gender differences in protein kinase G vasorelaxation of rat aorta
149. Soy protein dietary supplementation containing phytoestrogens improves lipid profiles and blood pressure: A double blind, randomised, placebo controlled study in men and postmenopausal women
150. A placebo controlled trial of transdermal estrogen replacement therapy in postmenopausal women: Effects on arterial compliance and endothelial function
151. A placebo controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: Effects on arterial compliance and endothelial function
152. Unstable angina
153. Risks of coronary heart disease in women: Current understanding and evolving concepts
154. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
155. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate
156. Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules
157. Cardiovascular disease risk and hormone replacement therapy (HRT): A review based on randomised, controlled studies in postmenopausal women
158. A clinical trial of estrogen-replacement therapy after ischaemic stroke
159. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys
160. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
161. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomised controlled trial
162. Induction of calcium-dependent nitric oxide synthases by sex hormones
163. Estrogen restores endothelial cell function in an experimental model of vascular injury
164. Progestins and androgens
165. Estrogen modulates responses of atherosclerotic coronary arteries
166. A comparison of tibolone and hormone replacement therapy on coronary artery and myocardial function in ovariectomised atherosclerotic monkeys
167. Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies
168. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: A multicenter, double-blind, randomised study
169. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: Evidence from a national cohort
170. World Health Organization-International Society of Hypertension (WHO-ISH) Guidelines Subcommittee
171. Established and emerging cardiovascular risk factors
172. Tibolone prevents atherosclerotic lesion formation in cholesterol fed ovariectomised rabbits